Business
GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting
Advancing Gene-Directed Prodrug Therapy: Data Presented at AACR Supports Gedeptin's Potential in Solid Tumors ATLANTA, GA - April 29, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunother...
About this update from Geovax Labs, Inc.
[{"type":"image","caption":"","headline":"GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"Advancing Gene-Directed Prodrug Therapy: Data Presented at AACR Supports Gedeptin's Potential in Solid Tumors","length":113,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - April 29, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of new clinical data on its gene-directed enzyme prodrug therapy, Gedeptin(R), at the American Association for Cancer Research (AACR) Annual Meeting 2025, being held April 2530 in Chicago, IL.","length":425,"tagName":"p"},{"type":"text","content":"The presentation, titled "Viral-Vectored, Gene-Directed Prodrug Therapy (Gedeptin) in Needle-Accessible Solid Tumors," was delivered by J. Marc Pipas, M.D., Executive Medical Director, Oncology at GeoVax, during the Phase II Clinical Trials 1 Poster Session on April 29, 2025. The session drew significant interest from researchers and clinicians, underscoring the growing recognition of Gedeptin's therapeutic potential. The corresponding abstract was published in the AACR journal Cancer Research.","length":513,"tagName":"p"},{"type":"text","content":"Key Findings from the Clinical Study","length":36,"tagName":"p"},{"type":"text","content":"The study, conducted in collaboration with researchers from Stanford Cancer Center, Emory University School of Medicine, Vanderbilt University, and Thomas Jefferson University, evaluated the safety and efficacy of repeated cycles of Gedeptin in patients with advanced head and neck cancer (H&N Ca).","length":302,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Trial Design: Up to five treatment cycles were administered, each consisting of intratumoral (IT) injection of Gedeptin followed by intravenous (IV) administration...